Clinical Studies

In this December 2004 analytic lab study by Dr. John W. Roberts, PhD of the Natural-Immunogenics Corporation, the antimicrobial effects of two different forms of colloidal silver were tested. The ‘particulate’ (i.e., metallic) form of colloidal silver was tested against the (free) ‘ionic’ form of colloidal silver.

In this clinical study, published in the Journal of Applied Technology in February 2014, the researchers treated human liver HepG2 cells (i.e., liver cancer cells) and human colon Caco2 cells (i.e., colorectal cancer cells) with silver nanoparticles with an average size of 20.4 nm in order to evaluate their toxicity to the cells.

In this clinical study, published in the journal Applied Biochemistry and Biotechnology in April 2015, researchers found that when human promyelocytic leukemia cells (HL-60) and “human monocyte cells” (U-937) from a lymphoma cancer cell line were exposed to silver nanoparticles of 25 ppm concentration, the “viability of HL-60 cells (i.e., leukemia cells) diminished to about 60 % in the presence of AgN at concentration of 25 mg/l regardless of the length of the exposure time.

In this clinical study, published in the journal Biochemical and Biophysical Research Communications in December 2009, researchers tested silver nanoparticles on HeLa cells (cervical cancer cells) to determine their biological effects.

In this clinical study, published in the International Journal of Pharmacy and Pharmaceutical Sciences in 2014 (Vol. 6, Issue 8), researchers studied the effects of silver nanoparticles on hepatocellular carcinoma cell line Hep3B, i.e., a liver cancer cell line.

In this clinical study published in the Archives of Toxicology in July 2011, researchers discovered that when a human lung cancer cell line A549 was exposed to silver nanoparticles, reactive oxygen species (ROS) was produced resulting in mitochondrial damage to the cancer cells and “early apoptosis” (i.e., cellular self-destruction).

In this clinical study, published in the Journal of Applied Toxicology in November 2013, the researchers set out to investigate how AgNPs of different sizes interact with two different tumoral human cell lines, i.e., hepatoma [HepG2] and leukemia [HL-60], i.e., liver cancer cells and blood cancer cells.

In this clinical study, published in the journal BioMedical Research International in 2013, researchers set out to evaluable the toxicity of silver nanoparticles against human breast cancer cells (MDA-MB-231).

In this clinical study, published in the International Journal of Nanomedicine in June 2015, researchers demonstrated that silver nanoparticles were highly toxic to triple-negative breast cancer cells (TNBC) “at doses that have little effect on non-tumorigenic breast cells or cells derived from liver, kidney, and monocyte lineages.”

In this December 2015 clinical study published in the Journal of Nanobiotechnology, researchers demonstrated silver nanoparticles have a potent inhibitory effect on biofilm formation in the Candida albicans species of fungal pathogen.

In this clinical study, published in June 2013 and titled “Effect of Silver Nanoparticles on Common Bacteria in Hospital Surfaces,” researchers from the Infectious and Tropical Diseases Research Center, University of Medical Sciences, Ahvaz, Iran, tested three different concentrations of silver nanoparticles – 100 ppm, 200 ppm and 300 ppm – on surface colonies of infectious microbes including MRSA, Pseudomonas aeuroginosa and Bacillus cereus.

Dr. Robert O. Becker’s classic study on healing wounds with electrically generated silver ions.

The Silver Nanotechnology Working Group demonstrates the history and safety of commercial products containing silver nanoparticles.

This is an impressive 2011 White Paper by Systagenix Wound Management, explaining the scientific basis for the use of silver dressings in wound management and clinical practice, and providing a general background on silver as an antimicrobial, including details on its mode of action, potential for resistance and safety profile, as well as an overview of the current available commercial silver dressings.

This critical review of the medical literature dating back to the early 1900’s demonstrates that it is soluble silver compounds such as silver nitrate, silver chloride, silver acetate, silver protein and others that are responsible for the vast majority of cases of skin-staining (i.e., argyria) reported in the medical literature.

In this clinical study, published in the journal Toxicology In Vitro in July 2014, clinical researchers set out to evaluate the effects of silver nanoparticles against human colon cancer cells. The researchers tested “the size-dependent effects of AgNPs by treating the human LoVo cell line, an intestinal epithelium model, with spherical AgNPs of well-defined sizes (10, 20, 40, 60 and 100nm).”

Spray silver disinfectant products are ruled safe for use on food contact surfaces by EPA.

American Biotech Labs has just released what is believed to be the first ever human ingestion safety study on a colloidal silver supplement.

This is an abstract of a 2012 study published in the journal Nanotoxicology, in which researchers tested silver nanoparticles for genotoxicity, acute oral and dermal toxicity, eye and dermal irritation and corrosion, and skin sensitization.

In this study, published in the International Journal of Nanomedicine, November 2015, researchers concluded that silver nanoparticles “exhibited an excellent antibacterial activity against Methicillin-Resistant S. aureus (MRSA), Acinetobacter baumannii, Enterococcus faecalis, and Escherichia coli.”

In this clinical study, published in the International Journal of Nanomedicine in November 2013, researchers used specially prepared silver nanoparticles against breast cancer cells (MDA-MB-231).

Silver has been used for at least six millennia to prevent microbial infections, and was the most important antimicrobial agent available before the introduction of antibiotics.

In this study, published in the Journal of Ocular Pharmacology and Therapeutics in March 2013, the study authors focused on determining whether or not silver nanoparticles could be used as an effective treatment for fungal keratitis, which is emerging as a “major cause of vision loss” in China and other developing nations due largely to the unavailability of effective antifungals.

Colloidal silver proven effective against multi-drug resistant Pseudomonas aeruginosa, one of the most deadly drug-resistant pathogens.

In this clinical study, published in the journal Environmental Science & Technology in August 2009, silver nanoparticles were tested in very small concentrations on human hepatoma cell line HepG2 (a liver cancer cell line). The silver-treated cells were then compared to cells treated with polystyrene nanoparticles and silver carbonate (a chemical silver compound) in order to “test the toxic effects with respect to different raw chemical compositions and forms of silver.”